CKDXF Opthea Ltd IFRS Annual reports only
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1815620 · Fiscal year ends 06/30
Financial factors as of 2023-06-30 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 | FY20212021-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $25,000 | $125,000 | $108,000 | $90,683 | $68,613 |
| R&D expense | $126.83M | $176.33M | $128.83M | $81.45M | $25.89M |
| Operating income | -$155.76M | -$191.84M | -$150.03M | -$96.54M | — |
| Interest expense | $46.46M | $30.26M | $13.46M | $0 | $5,782 |
| Pretax income | -$169.74M | -$229.65M | -$148.45M | -$99.12M | -$50.28M |
| Income tax | -$6.95M | -$9.41M | -$5.93M | -$6.30M | -$4.94M |
| Net income | -$162.79M | -$220.24M | -$142.52M | -$92.82M | -$45.34M |
| EBITDA | -$155.75M | -$191.82M | -$150.01M | -$96.53M | — |
| EPS (basic) | -0.13 | -0.35 | -0.32 | -0.26 | -0.14 |
| EPS (diluted) | -0.13 | -0.35 | -0.32 | -0.26 | -0.14 |
| Weighted avg. shares (diluted) | 1.22B | 638.20M | 442.64M | 351.56M | 320.43M |
| Balance sheet | |||||
| Cash & equivalents | $48.44M | $172.47M | $89.19M | $44.63M | $118.19M |
| Receivables | $419,000 | $1.43M | $636,564 | $257,668 | $565,286 |
| Current assets | $56.80M | $188.19M | $98.39M | $59.91M | $138.12M |
| PP&E, netmay include right-of-use assets (IFRS) | $0 | $48,000 | $33,035 | $28,082 | $23,259 |
| Total assets | $56.80M | $188.79M | $98.64M | $60.05M | $138.41M |
| Current liabilities | $257.87M | $64.06M | $18.74M | $12.04M | $3.11M |
| Short-term debt | $9.74M | $38.06M | $17.84M | $11.40M | $2.42M |
| Total liabilities | $257.87M | $264.60M | $104.49M | $12.07M | $3.12M |
| Shareholders' equity | -$201.07M | -$75.81M | -$5.85M | $47.98M | $135.29M |
| Cash flow statement | |||||
| Operating cash flow | -$158.64M | -$161.01M | -$120.61M | -$71.33M | -$45.55M |
| Capital expenditure | $13,000 | $33,000 | $22,000 | $16,910 | $12,702 |
| Free cash flow | -$158.66M | -$161.05M | -$120.63M | -$71.35M | -$45.56M |
| Investing cash flow | -$13,000 | -$33,000 | -$22,000 | -$16,910 | $656,482 |
| Financing cash flow | $34.77M | $243.73M | $167.28M | $171,597 | $116.94M |
| Depreciation & amortization | $7,000 | $19,000 | $17,000 | $11,917 | $15,012 |
| Stock-based compensation | $6.13M | $5.08M | $5.83M | $5.25M | $3.90M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.